ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0122

Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program

Jeong Yee1, Emily G. Oakes1, May Choi2, Candace Feldman1, Elizabeth Karlson1 and Karen Costenbader3, 1Brigham and Women's Hospital, Boston, MA, 2University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, mental health, rheumatoid arthritis, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0117–0144) Epidemiology & Public Health Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular disease (CVD) risk is increased for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Mental health conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD) are not traditional CVD risk factors but have been associated with CVD risk and are highly prevalent in SLE and RA populations. We assessed the contribution of these 3 mental health conditions related to stress and emotional distress to CVD risk among patients with RA and/or SLE in a large, diverse U.S. cohort.

Methods: We used data from the All of Us Research Program (v7), a NIH cohort with >287,000 adult participants in the U.S. who gave consent for linkage to their electronic health records. RA/SLE patients were identified by ≥2 ICD-9, ICD-10, or SNOMED codes >2 months apart within 2 years of enrollment. We excluded patients with acute myocardial infarction (MI) and stroke at baseline (1 year pre-enrollment). Depression, anxiety, and PTSD were identified by ICD-9/10, and SNOMED codes in the baseline period. The primary outcome was a composite of acute MI, stroke (identified by ICD9/10 and SNOMED codes), and all-cause mortality. Patients were followed until the 1st acute MI, stroke, or death, through 4 years or end of study period (July 1, 2022). Covariates included age, sex, and race/ethnicity, income, educational level, smoking, obesity, and comorbidities. We estimated incidence rates (IRs) and incidence rate ratios (IRRs). Adjusted Cox regression models compared risks of the endpoint of acute MI, stroke, or all-cause mortality among RA/SLE patients with and without these 3 mental health conditions.

Results: We studied 3,825 patients with RA only, 1,862 with SLE (including 383 with meeting both definitions). Among them,1,790 (31.5%) had depression, anxiety, and/or PTSD (Table 1). Compared to patients without, those with ≥1 mental health conditions were more likely to be less educated, in a low-income group, to have ever smoked, to be obese, and to have comorbidities. Patients were followed for a mean of 31.0 months (SD 14.7). 155 events (64 MI, 55 strokes and 36 deaths) occurred among RA/SLE patients with mental health conditions in 55,856 person-months (IR 33.3/1000 person-years) vs. 232 (75 MI, 117 strokes and 40 deaths) among those without mental health diagnoses in 120,422 person-months (IR 23.1/1000 person-years; IRR 1.44). The risk of acute MI, stroke, and death was significantly higher among patients with these mental health conditions than without for both RA and SLE (Figure 1). After adjustment for smoking, obesity, and Charlson comorbidity index, the HR of incidence of MI, stroke, or all-cause mortality for patients with concomitant mental health conditions was 1.28 (95% CI 1.02-1.60, Table 2).

Conclusion: In this large diverse U.S. cohort of patients with RA/SLE without prior CVD events, depression, anxiety and PTSD were associated with increased risk of developing acute MI, stroke, or death. These results suggest greater awareness of increased CVD risk among rheumatic disease patients with concurrent mental health conditions is needed. Research is ongoing to dissect the likely multifactorial causal pathways underlying this relationship.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Yee: None; E. Oakes: None; M. Choi: AbbVie/Abbott, 2, 6, Amgen, 2, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 2, 6, Celgene, 2, 6, Eli Lilly, 2, 6, GlaxoSmithKlein(GSK), 2, Janssen, 2, 6, Mallinckrodt, 2, Merck/MSD, 2, MitogenDx, 2, Organon, 6, Pfizer, 2, 6, Roche, 2, Werfen, 2; C. Feldman: BMS Foundation, 5, Curio Bioscience, 12, My husband is one of the founders and will receive equity (but has not received anything to date)., OM1, Inc., 2, Pfizer, 5; E. Karlson: None; K. Costenbader: Amgen, 2, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 2, Cabaletta, 2, Eli Lilly, 2, Exagen Diagnostics, 5, Gilead, 5, GlaxoSmithKlein(GSK), 2, 5, Janssen, 2, 5.

To cite this abstract in AMA style:

Yee J, Oakes E, Choi M, Feldman C, Karlson E, Costenbader K. Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/depression-anxiety-and-post-traumatic-stress-disorder-in-association-with-cardiovascular-disease-among-patients-with-systemic-lupus-erythematosus-and-rheumatoid-arthritis-in-the-all-of-us-research-pr/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-anxiety-and-post-traumatic-stress-disorder-in-association-with-cardiovascular-disease-among-patients-with-systemic-lupus-erythematosus-and-rheumatoid-arthritis-in-the-all-of-us-research-pr/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology